person · Reporting owner

WILLIAMS DONALD A

Disclosed activity across 2 companies

Tapewire entity: 89237
SEC CIK: 0001241435

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
Akari Therapeutics PlcAKTX · Entity 7692	Director	June 28, 2024	July 02, 2024
Western New England Bancorp, Inc.WNEB · Entity 6063	Director	May 23, 2017	May 25, 2017

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

Akari Therapeutics Plc

Report date June 28, 2024 · Filed July 02, 2024

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.00 · Expires 2034-06-28	Direct	5,000,000	Reported balance After 2024-06-28 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2024-06-28 · Grant · Acquired 5,000,000 · Balance 5,000,000 F1: The stock options have an exercise price of $0.001395 per ordinary share, par value $0.0001 per share ("Ordinary Share"). F2: Non-qualified stock option granted under the Issuer's 2023 Equity Incentive Plan. One-hundred percent (100%) of the stock option vests and becomes exercisable on the date of the Issuer's 2025 Annual General Meeting of Shareholders, subject to continued service with the Issuer. F3: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents 2,000 Ordinary Shares.

Filing footnotes · ownership attribution and instrument terms

F1: The stock options have an exercise price of $0.001395 per ordinary share, par value $0.0001 per share ("Ordinary Share").

F2: Non-qualified stock option granted under the Issuer's 2023 Equity Incentive Plan. One-hundred percent (100%) of the stock option vests and becomes exercisable on the date of the Issuer's 2025 Annual General Meeting of Shareholders, subject to continued service with the Issuer.

F3: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents 2,000 Ordinary Shares.

Western New England Bancorp, Inc.

Report date May 23, 2017 · Filed May 25, 2017

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common Stock, par value $.01 per shareSEC Table I · non-derivative	Direct	1,773	Reported balance After 2017-05-23 transaction · row 1 1 source row Row 1 · 2017-05-23 · Grant · Acquired 1,773 · Balance 1,773 F1: Represents an award of restricted stock under the 2014 Omnibus Plan, which vests on the first anniversary of the grant.
Common Stock, par value $.01 per shareSEC Table I · non-derivative	IndirectBy Karen F. Williams 2004 Family Trust	213,320	Reported balance Holding disclosure · report date 2017-05-23 · row 2 Holding and transaction disclosures are not merged. 1 source row Row 2 · Balance 213,320

Filing footnotes · ownership attribution and instrument terms

F1: Represents an award of restricted stock under the 2014 Omnibus Plan, which vests on the first anniversary of the grant.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
June 28, 2024 Filed Jul 2, 2024 16:30 UTC	Akari Therapeutics Plc AKTX · Entity 7692	GrantStock Option (Right to Buy) · Derivative	5,000,000	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0000950170-24-080541 · ownership.xml · derivative · entry 1 WILLIAMS DONALD A · CIK 0001241435 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,000,000 Underlying: Ordinary Shares, par value $0.0001 per share · 5,000,000 shares Expires 2034-06-28 F1 · derivative.exercise_price: The stock options have an exercise price of $0.001395 per ordinary share, par value $0.0001 per share ("Ordinary Share"). F2 · derivative.exercise_date: Non-qualified stock option granted under the Issuer's 2023 Equity Incentive Plan. One-hundred percent (100%) of the stock option vests and becomes exercisable on the date of the Issuer's 2025 Annual General Meeting of Shareholders, subject to continued service with the Issuer. F3 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents 2,000 Ordinary Shares. Read SEC document
May 23, 2017 Filed May 25, 2017 21:29 UTC	Western New England Bancorp, Inc. WNEB · Entity 6063	GrantCommon Stock, par value $.01 per share	1,773	$0.00	$0.00	Disclosure SEC source: 0001123292-17-001018 · edgar.xml · nonDerivative · entry 1 WILLIAMS DONALD A · CIK 0001241435 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,773 F1 · shares: Represents an award of restricted stock under the 2014 Omnibus Plan, which vests on the first anniversary of the grant. Read SEC document
December 20, 2016 Filed Dec 21, 2016 21:17 UTC	Western New England Bancorp, Inc. WNEB · Entity 6063	GiftCommon Stock	725	$0.00	$0.00	Disclosure SEC source: 0001123292-16-003092 · edgar.xml · nonDerivative · entry 1 WILLIAMS DONALD A · CIK 0001241435 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By the Karen F. Williams 2004 Family Trust Disclosed balance after: 213,320 Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.